These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 35807171)

  • 41. PCSK9 targets important for lipid metabolism.
    Schulz R; Schlüter KD
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):2-11. PubMed ID: 28176216
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recent patents on PCSK9: a new target for treating hypercholesterolemia.
    Li H; Li H; Ziegler N; Cui R; Liu J
    Recent Pat DNA Gene Seq; 2009; 3(3):201-12. PubMed ID: 19601924
    [TBL] [Abstract][Full Text] [Related]  

  • 43. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
    Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
    Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nucleic Acid-Based Therapies for Atherosclerosis.
    Mäkinen P; Ruotsalainen AK; Ylä-Herttuala S
    Curr Atheroscler Rep; 2020 Feb; 22(2):10. PubMed ID: 32034521
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting angiopoietin-like 3 in atherosclerosis: From bench to bedside.
    Ling P; Zheng X; Luo S; Ge J; Xu S; Weng J
    Diabetes Obes Metab; 2021 Sep; 23(9):2020-2034. PubMed ID: 34047441
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition.
    Tibolla G; Norata GD; Artali R; Meneghetti F; Catapano AL
    Nutr Metab Cardiovasc Dis; 2011 Nov; 21(11):835-43. PubMed ID: 21943799
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Future of Lipid-lowering Therapy.
    Zwol WV; Rimbert A; Kuivenhoven JA
    J Clin Med; 2019 Jul; 8(7):. PubMed ID: 31340607
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future.
    Shimada YJ; Cannon CP
    Eur Heart J; 2015 Sep; 36(36):2415-24. PubMed ID: 25971287
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
    Della Badia LA; Elshourbagy NA; Mousa SA
    Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L; Robinson JG
    Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inclisiran-Silencing the Cholesterol, Speaking up the Prognosis.
    Rogula S; Błażejowska E; Gąsecka A; Szarpak Ł; Jaguszewski MJ; Mazurek T; Filipiak KJ
    J Clin Med; 2021 Jun; 10(11):. PubMed ID: 34199468
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Emerging biologic therapies for hypercholesterolaemia.
    Pucci G; Cicero AF; Borghi C; Schillaci G
    Expert Opin Biol Ther; 2017 Sep; 17(9):1077-1087. PubMed ID: 28617192
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Angiopoietin-Like 3 (ANGPTL3) and Atherosclerosis: Lipid and Non-Lipid Related Effects.
    Lupo MG; Ferri N
    J Cardiovasc Dev Dis; 2018 Jul; 5(3):. PubMed ID: 30011918
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect?
    Sahebkar A; Watts GF
    Cardiovasc Drugs Ther; 2013 Dec; 27(6):559-67. PubMed ID: 23913122
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel treatment options for the management of heterozygous familial hypercholesterolemia.
    Polychronopoulos G; Tziomalos K
    Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1375-1381. PubMed ID: 28884604
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9.
    German CA; Shapiro MD
    BioDrugs; 2020 Feb; 34(1):1-9. PubMed ID: 31782112
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia.
    Banerjee Y; Pantea Stoian A; Cicero AFG; Fogacci F; Nikolic D; Sachinidis A; Rizvi AA; Janez A; Rizzo M
    Expert Opin Drug Saf; 2022 Jan; 21(1):9-20. PubMed ID: 34596005
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
    Ling H; Burns TL; Hilleman DE
    Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis.
    Wright RS; Ray KK; Raal FJ; Kallend DG; Jaros M; Koenig W; Leiter LA; Landmesser U; Schwartz GG; Friedman A; Wijngaard PLJ; Garcia Conde L; Kastelein JJP;
    J Am Coll Cardiol; 2021 Mar; 77(9):1182-1193. PubMed ID: 33663735
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting RNA With Antisense Oligonucleotides and Small Interfering RNA: JACC State-of-the-Art Review.
    Katzmann JL; Packard CJ; Chapman MJ; Katzmann I; Laufs U
    J Am Coll Cardiol; 2020 Aug; 76(5):563-579. PubMed ID: 32731935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.